United States Patent 10,265,265: Claim Scope, Expiration, Orange Book Position and Generic Risk

U.S. Patent No. 10,265,265 protects aqueous topical compositions containing calcipotriol or calcipotriol monohydrate and betamethasone or a betamethasone ester in a polyaphron dispersion. The patent is directed to formulation architecture rather than the active ingredients alone. Its principal limitations are the aqueous continuous phase, oil-based discontinuous droplets, alkaline-to-neutral pH, and, for independent claim 1, accelerated-storage stability.

The patent is closely associated with the formulation technology used for Wynzora, an FDA-approved calcipotriene and betamethasone dipropionate cream marketed by MC2 Therapeutics. The core commercial risk is highest for topical products that reproduce the same polyaphron or PAD formulation structure, rather than for conventional ointments, gels, foams, or suspensions using different delivery systems.

What does U.S. Patent 10,265,265 protect?

The patent protects a topical aqueous composition with five central characteristics:

A polyaphron dispersion.
Water in the continuous phase.
A pharmaceutically acceptable oil in the discontinuous phase.
Calcipotriol or calcipotriol monohydrate and betamethasone or a betamethasone ester in the oil droplets.
A composition pH from 7.0 to 8.5.

Claim 1 adds a chemical-stability limitation requiring no more than a 5% reduction in each active ingredient after three months in a sealed glass container at 40°C.

Independent claim 13 is broader in one important respect. It permits the two active ingredients to be located in the same droplets or in separate droplets and requires that the listed calcipotriol and betamethasone compounds be the sole pharmacologically active compounds. Claim 13 does not place the stability limitation in its base form, although dependent claim 25 adds it.

Claim feature	Claim 1	Claim 13
Aqueous composition	Yes	Yes
Polyaphron dispersion	Yes	Yes
Water in continuous phase	Yes	Yes
Oil-based discontinuous phase	Yes	Yes
Calcipotriol or monohydrate	Yes	Yes
Betamethasone or ester	Yes	Yes
Actives located in droplets	Yes	Yes
Same or separate droplets permitted	Not expressly stated	Yes
Water content	5% to 90%	5% to 90%
pH	7.0 to 8.5	7.0 to 8.5
Sole pharmacologically active compounds	No	Yes
Three-month, 40°C stability limit	Yes	No, unless claim 25 applies

The claims do not require a particular indication, strength, package, dosing schedule, container closure, or commercial product name.

How does a polyaphron dispersion limit the patent’s scope?

A polyaphron dispersion is a high-internal-phase emulsion system in which oil droplets are dispersed in a continuous aqueous phase and stabilized by surfactant structures. The formulation can contain a high proportion of discontinuous oil phase, including the 60% to 95% range recited in claims 11 and 23.

This architecture distinguishes the patent from conventional topical dosage forms:

An ointment with no aqueous continuous phase would generally fall outside the independent claims.
A conventional oil-in-water emulsion may avoid infringement if it is not a polyaphron dispersion as properly construed.
A water-in-oil cream would face a different claim-mapping analysis because the claims require water in the continuous phase and oil in the discontinuous phase.
A foam, aerosol, or suspension may avoid the claims if it lacks the required dispersion structure.
A product with the actives dissolved only in the continuous aqueous phase would face a strong non-infringement position if the claims require their presence in droplets.

The term “polyaphron dispersion” is likely to be a principal construction issue in litigation. The intrinsic evidence, specification, prosecution history, microscopy, droplet-size data, internal-phase volume, surfactant system, and manufacturing process would determine whether a competing formulation has the claimed structure.

What active ingredients and oils are covered?

The claims cover either calcipotriol or calcipotriol monohydrate, combined with either betamethasone or an ester of betamethasone. Claim 28 narrows the combination to calcipotriol and a betamethasone ester. Claim 29 identifies betamethasone dipropionate.

The commercially important combination is:

Calcipotriol, also called calcipotriene in U.S. regulatory materials.
Betamethasone dipropionate.

The patent does not limit the claims to betamethasone dipropionate in its independent claims. Other betamethasone esters can potentially fall within the literal language if the remaining structural and compositional requirements are met.

Claim 2 and its counterpart claim 14 identify several oil classes:

Monoglycerides
Diglycerides
Triglycerides
Isopropyl myristate
Mixtures of those materials

These are exemplary dependent-claim limitations. A formulation using another pharmaceutically acceptable oil could still fall within claim 1 or claim 13 if the oil meets the broader requirement of being immiscible or substantially immiscible with the aqueous continuous phase.

What formulation components are protected?

The dependent claims create several formulation subgroups.

Dependent claims	Protected feature
2, 14	Monoglyceride, diglyceride, triglyceride, isopropyl myristate or mixture
3, 15	Xanthan gum, or isopropyl alcohol with neutralized polyacrylic acid
4, 16	Water content of 15% to 90%
5, 17	Water content of 5% to 50%
6, 18	C1-C10 alcohol or polyether-type compound
7, 19	Propylene glycol, glycerol, ethanol, isopropyl alcohol or mixture
8, 20	pH of 7.25 to 7.75
9, 21	Gelling agent
10, 22	Permeation enhancer
11, 23	Discontinuous phase of 60% to 95%
12, 24	Continuous phase of 5% to 40%
25	Stability limitation
26, 27	Water content of 10% to 90%
28, 30	Calcipotriol plus betamethasone ester
29, 31	Betamethasone dipropionate

Claims 4, 5 and 26 create overlapping water-content ranges. The overlap gives the patent multiple fallback positions if a broader water-range claim is challenged.

The pH limitation is commercially significant. Many conventional calcipotriol formulations operate under different pH conditions because calcipotriol and betamethasone dipropionate have different stability and solubility profiles. A competing product adjusted to a pH below 7.0 or above 8.5 could seek to avoid the independent claims, subject to formulation-performance and equivalents analysis.

When does U.S. Patent 10,265,265 lose exclusivity?

The patent issued on April 23, 2019. Its nominal term is based on the earliest effective nonprovisional priority date and is projected to expire around April 2, 2034, before any applicable patent-term adjustment or extension. The effective expiration date should be confirmed against the USPTO patent-term data and any terminal disclaimer.

Milestone	Date or status
U.S. patent	10,265,265
Grant date	April 23, 2019
Nominal projected expiration	Around April 2, 2034
Patent-term adjustment	Must be checked in the USPTO record
Patent-term extension	No extension is established from the claim text alone
Regulatory exclusivity of Wynzora	Separate from patent term

Patent expiration and FDA regulatory exclusivity are separate rights. FDA approval of Wynzora does not itself establish the patent’s expiration date, and the patent does not automatically prevent every competing calcipotriene/betamethasone product after approval.

What is the FDA and Orange Book status?

Wynzora cream was approved by FDA in 2020 for the topical treatment of plaque psoriasis in patients 12 years of age and older. The product contains calcipotriene and betamethasone dipropionate and uses a PAD-based formulation platform.[2]

FDA Orange Book listings provide the regulatory framework for generic applicants that seek approval of a therapeutically equivalent product through an abbreviated new drug application. A listed patent can trigger a Paragraph IV certification, a 30-month stay in the circumstances specified by the Hatch-Waxman statute, and patent litigation if the patent holder files suit within the statutory period.[3]

The patent’s practical Orange Book relevance depends on:

Whether U.S. Patent 10,265,265 is listed against the relevant Wynzora reference product.
The precise listed claims and use codes.
Whether a proposed generic’s ANDA product is required to contain the claimed formulation.
Whether the generic applicant makes a Paragraph IV certification.
Whether the patent owner files an infringement action within 45 days.

The claim text alone does not establish the current Orange Book listing status, the number of listed Wynzora patents, or the existence of a particular ANDA challenge.

Which companies are challenging U.S. Patent 10,265,265?

A Paragraph IV challenge cannot be inferred merely from the existence of a patent or an FDA-approved product. The relevant public indicators are an FDA Orange Book certification, a patent-holder litigation complaint, a district-court docket, or an inter partes review petition.

The commercial challengers most likely to evaluate this patent are manufacturers of:

Generic calcipotriene and betamethasone dipropionate creams.
Alternative topical emulsions containing both actives.
Products seeking substitutability or therapeutic equivalence to Wynzora.
Formulations using the same PAD or polyaphron technology under a private-label or licensing arrangement.

A generic applicant can pursue several positions:

Paragraph III certification: No launch before patent expiration.
Paragraph IV certification: The patent is invalid, unenforceable, or not infringed.
Section viii statement: The applicant omits a patented method of use, where applicable.
Non-infringement by formulation design: The product does not contain a polyaphron dispersion, does not place both actives in droplets, or falls outside the pH and water ranges.

The strongest Paragraph IV arguments would likely focus on claim construction, anticipation or obviousness of the polyaphron system, enablement of the broad composition claims, and whether the accelerated stability limitation is definite and sufficiently supported.

How strong is the patent estate?

U.S. Patent 10,265,265 has meaningful formulation strength but narrower coverage than a patent claiming calcipotriol and betamethasone dipropionate as active ingredients without a delivery-system limitation.

Strengths

The independent claims combine active-ingredient coverage with a specific physical formulation architecture.
Claim 13 allows the actives to be present in the same or separate droplets.
The claims include broad oil, water, and pH ranges.
Dependent claims cover common excipients and manufacturing-relevant formulation choices.
The stability limitation in claim 1 can distinguish unstable prior-art emulsions.

Vulnerabilities

The claims depend heavily on proving that a product is a polyaphron dispersion.
The independent claims require water in the continuous phase and oil in the discontinuous phase.
The pH range excludes products outside 7.0 to 8.5.
Claim 13 is limited to products in which calcipotriol and betamethasone compounds are the sole pharmacologically active compounds.
Broad ranges may create prior-art and obviousness issues if earlier references disclose overlapping compositions.
The 5% stability limitation may create analytical and claim-construction disputes.

The estate is strongest against a product designed to replicate Wynzora’s internal-phase oil droplets, aqueous continuous phase, neutral-to-alkaline pH, and active loading. It is weaker against a non-polyaphron product that uses a chemically different delivery system.

What generic launch scenarios exist?

Launch before patent expiration

A pre-expiration launch would generally require one of four outcomes:

Successful invalidity or non-infringement litigation.
A settlement permitting an earlier launch.
A product design that avoids the asserted claims.
A license from the patent holder or technology licensor.

Launch at patent expiration

A conventional generic manufacturer could launch after the effective patent term ends if FDA approval is otherwise available. The manufacturer would still need to address any additional listed patents, regulatory exclusivity, trademarks, trade dress, and other formulation or manufacturing rights.

Non-infringing alternative formulation

A competitor could target:

A non-polyaphron emulsion.
A formulation with oil in the continuous phase.
A composition outside the claimed pH range.
A product in which one or both actives are not present in oil droplets.
A product with a different active combination or additional pharmacologically active ingredient, although that strategy may affect regulatory substitutability.

Avoiding one claim element is not sufficient if another patent in the broader commercial estate covers the alternative.

How does the patent compare with older calcipotriol and betamethasone patents?

Older calcipotriol and betamethasone patents generally addressed the active combination, treatment of psoriasis, conventional dosage forms, or specific combinations of concentrations. Many early rights associated with Taclonex and related products have expired or are approaching the end of their enforceable terms.

U.S. Patent 10,265,265 differs in three ways:

Issue	Older combination patents	U.S. 10,265,265
Core subject	Active combination or treatment	Polyaphron aqueous formulation
Key limitation	Drug identity, dose or use	Droplet structure, phase arrangement, pH and water
Main design-around route	Different active or indication	Different delivery architecture

This patent therefore operates as a later-generation formulation barrier. It can preserve exclusivity for a specific commercial product even when basic active-ingredient or treatment patents no longer block generic development.

What manufacturing and licensing barriers matter?

The patent covers composition attributes, but the commercial barrier may also include know-how relating to:

Formation of the high-internal-phase dispersion.
Surfactant selection and concentration.
Droplet-size control.
Order of ingredient addition.
Temperature and shear conditions.
Active loading into the oil phase.
pH adjustment without destabilizing the dispersion.
Scale-up and filling into commercial packaging.

A competitor can avoid literal infringement yet face development barriers if the alternative formulation does not achieve comparable stability, spreadability, drug release, skin penetration, or patient usability.

MC2 Therapeutics developed and commercialized the PAD technology associated with Wynzora. The commercial structure includes product rights, formulation know-how, manufacturing arrangements, and possible regional licenses. Specific license terms are not established by the claim text and should not be treated as equivalent to patent ownership.

What patent litigation affects the product?

The relevant litigation questions are:

Has the patent owner sued an ANDA applicant?
Was the suit filed within 45 days of a Paragraph IV notice?
Is U.S. Patent 10,265,265 one of several asserted patents?
Has a court construed “polyaphron dispersion”?
Has any court addressed the stability limitation?
Is there a settlement with an agreed generic launch date?
Has any patent claim been cancelled, amended, or disclaimed?

The patent number alone does not establish a pending case, a settlement, or an inter partes review proceeding. Those issues must be evaluated through PACER, PTAB records, FDA Orange Book updates, and SEC filings by relevant companies.

Key Takeaways

U.S. Patent 10,265,265 is a formulation patent covering aqueous polyaphron dispersions containing calcipotriol or calcipotriol monohydrate and betamethasone or a betamethasone ester.
The commercial focus is calcipotriol plus betamethasone dipropionate in a PAD-type topical cream.
Claims 1 and 13 are the principal independent claims.
Claim 1 includes a demanding three-month, 40°C stability limitation.
Claim 13 is broader regarding whether the actives occupy the same or separate droplets but requires them to be the sole pharmacologically active compounds.
The nominal patent expiration is around April 2, 2034, subject to USPTO term calculations.
The highest generic risk comes from products replicating the polyaphron structure, aqueous continuous phase, oil droplets, and pH range.
Non-polyaphron creams, foams, ointments, and alternative phase systems may offer design-around routes.
FDA approval and Orange Book listing must be analyzed separately from patent validity and enforceability.
The commercial patent position may include additional formulation patents, know-how, licenses, and manufacturing controls beyond this patent.

FAQs

Does U.S. Patent 10,265,265 cover all calcipotriene and betamethasone creams?

No. It requires a specific aqueous polyaphron dispersion with oil droplets, water in the continuous phase, and a pH from 7.0 to 8.5. A conventional cream may avoid the claims if it does not have the claimed phase structure.

Can a generic use betamethasone dipropionate and avoid the patent?

Possibly, but changing the active ingredient is not enough. The product must also avoid the claimed polyaphron dispersion, droplet localization, water range, pH range, or other required limitation.

Does claim 13 cover separate droplets for the two active ingredients?

Yes. Claim 13 expressly permits calcipotriol and the betamethasone compound to be present in the same droplets or in separate droplets.

Is the 40°C stability requirement present in every independent claim?

No. It is included in claim 1 and added to the claim 13 branch through dependent claim 25. Base claim 13 does not expressly include that stability limitation.

Does patent expiration automatically permit a generic Wynzora launch?

No. Launch timing also depends on FDA approval, any other Orange Book-listed patents, regulatory exclusivity, litigation outcomes, settlements, trademarks, and manufacturing or licensing constraints.

References

U.S. Patent No. 10,265,265. (2019). United States Patent and Trademark Office.
U.S. Food and Drug Administration. (2020). Wynzora cream prescribing information.
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
U.S. Patent and Trademark Office. (2024). Patent term adjustment and patent term information.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Mc2	WYNZORA	betamethasone dipropionate; calcipotriene	CREAM;TOPICAL	213422-001	Jul 20, 2020		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	07251094	Mar 15, 2007
United Kingdom	0723728.2	Dec 4, 2007

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	065740	⤷ Start Trial
Austria	E516797	⤷ Start Trial
Australia	2008224704	⤷ Start Trial
Canada	2680405	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 10,265,265

Which drugs does patent 10,265,265 protect, and when does it expire?

Summary for Patent: 10,265,265